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Although acute renal failure has been described in children with CF in relation to intravenous aminoglycoside use, there are no reports in
the adult CF literature. We describe 8 cases of acute renal failure in adult CF patients, all occurring during the use of intravenous
aminoglycosides for the treatment of pulmonary exacerbations with an epidemic multi-resistant Pseudomonas aeruginosa strain. Potential
contributory factors are discussed. These cases demonstrate another complication of infection by epidemic Pseudomonas strains in CF, and
confirm the need for effective segregation policies to prevent this.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Aminoglycoside therapy; Renal complications; Transmissible Pseudomonas aeruginosa; Cystic fibrosis1. Introduction
Cystic fibrosis patients chronically infected with Pseu-
domonas aeruginosa often require repeated courses of
intravenous antibiotics, many of which may be nephro-
toxic. In keeping with this, we have already demonstrated
that a significant proportion of adult CF patients have renal
impairment due to cumulative life time exposure to such
antibiotics [1]. Although there have been recent reports of
episodes of acute renal failure in children with CF [2,3],
there are no reported cases in the adult CF population. We
now present 8 cases of acute renal failure (ARF) in
patients attending the Liverpool Adult CF Unit (current
clinic population 185), all of which occurred in relation to
the use of intravenous aminoglycosides for pulmonary
exacerbations caused by chronic infection with the Liver-
pool epidemic P. aeruginosa strain (LES), which is
frequently multiresistant. Other potential contributory1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.05.017
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E-mail address: MWalshaw@doctors.org.uk (M.J. Walshaw).factors are discussed. Demographic data is given in the
Table 1.2. Case 1
Case 1 presented in April 2000 with a chest exacer-
bation with associated musculoskeletal chest wall pain
requiring diclofenac. Admission serum urea, creatinine and
electrolytes (U and E) were normal and he was
commenced on his usual dose of IV tobramycin 180 mg
tds (9.4 mg/kg/day) and IV colomycin 2 megaunits tds.
Tobramycin levels estimated pre- and 1 h post-4th dose
were within the protocol range (<1 mg/l and 7.8 mg/l
respectively). His chest improved but after 16 days, routine
tobramycin assay revealed trough and peak levels of 18
and 30 mg/l respectively. Urea was raised at 16.8 mmol/l
and creatinine at 231 Amol/l. Antibiotics and diclofenac
were stopped and IV hydration commenced. There was no
evidence of urinary infection and renal ultrasound was
normal. Renal function continued to deteriorate until day
20 (peak creatinine 331 Amol/l). U and E slowly returned4 (2005) 197 – 201ed by Elsevier B.V. All rights reserved.
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clearance (CrCl) 6 months later remained reduced at 58
ml/min (lower limit of normal range >80).3. Case 2
Case 2 presented in June 2003 with a chest exacerbation
associated with pleuritic chest pain. U and E was normal.
Spirometric measurement was impossible because of a
longstanding Bells Palsy. He was given IV tobramycin
160 mg tds (9.8 mg/kg/day, his usual dose), IV co-
trimoxazole (1.44 g bid) (for co-existing longstanding
Burkholderia cenocepacia infection), IV colomycin (2
megaunits tds) and diclofenac for his pain. Trough and
peak tobramycin levels around the 4th dose were satisfac-
tory. On day 10 he complained of dizziness, ataxia and
tinnitus. Aural examination was normal. Trough tobramycin
level was 8.9 and renal function was impaired (urea 23.4
mmol/l, creatinine 300 Amol/l). Urine was sterile. Renal
USS showed normal size kidneys. Tobramycin and diclo-
fenac were discontinued and IV rehydration commenced
with good effect. Serum U and E returned to normal by 21
days, but CrCl 4 months later was only 63 ml/min. CrCL
had previously been measured in July 2002 when he was
clinically stable at 86 mls/min.4. Case 3
Case 3 was maintained on azithromycin as an anti-
inflammatory agent. In November 2003 she started home IV
antibiotics (tobramycin 120 mg tds [8 mg/kg/day] and
colomycin 2 megaunits tds) for a pulmonary exacerbation.
Baseline U and E was normal. Serum tobramycin levels pre-
and 1 h post-4th dose were appropriate (0.4 and 9.3
respectively). On day 12 she developed a flu-like illness
and widespread inflammatory arthropathy (mainly wrists,
fingers and knees). Simple analgesia was ineffective and
Ibuprofen was commenced. On day 15 she developed
vomiting, dyspepsia, reduced oral intake and a 3 kg weight
loss. A random tobramycin level was 14.8 mg/l and urea
and creatinine were elevated (16 mmol/l and 265 Amol/lTable 1
Patient demographics
Case Sex Age Genotype FEV1 % predicted BMI
1 M 20 DF508/DF508 54 19.1
2 M 42 DF508/DF508 Bells palsy 20.2
3 F 21 DF508/DF508 46 19.2
4 F 20 DF508/DF508 43 20.0
5 F 52 DF508/R117H 30 15.5
6 F 19 DF508/DF508 48 20.1
7 F 19 DF508/DF508 60 19.8
8 F 18 DF508/DF508 98 23.0
Multiresistant = resistant to at least 2 of the 3 classes of antipseudomonal antibiorespectively). MSSU was negative and USS showed normal
kidneys with no obstruction.
Ibuprofen, azithromycin and antibiotics were discontin-
ued and IV rehydration commenced. Serum creatinine
peaked at 289 Amol/l on day 17 before gradually returning
to normal on day 25 (107 Amol/l), at which point CrCl was
37 mls/min.5. Case 4
Case 4 was listed for pulmonary transplantation, and
required prolonged courses of IV antibiotics, often carried
out at home, to achieve a clinical effect. In October 2000 U
and Es were normal. In December 2000 she undertook a
course of home IV tobramycin (160 mg tds :10.3 mg/kg/day
— her usual dose) and IV ceftazidime (3 g tds) and serum
tobramycin levels around the 4th dose were normal (0.9 and
8.3 respectively). By day 18 there had been little clinical
change and sputum cultures suggested reduced sensitivity to
ceftazidime, which was accordingly changed to IV colo-
mycin 2 megaunits tds. At day 25, azithromycin was added
in and the intravenous antibiotics continued unchanged.
Tobramycin levels remained in the therapeutic range. By
day 39, FEV1 had improved but she complained of nausea,
headache, dizziness and widespread artharalgia; BP rose to
180 /95, renal function deteriorated (urea 42.1 mmol/l and
creatinine 394 Amol/l) and a random tobramycin level was
high at 39. She was admitted to hospital, IV antibiotics and
azithromycin stopped, and rehydration started. Investigation
of the renal tract was unhelpful except for microscopic
haematuria. Marked peripheral blood eosinophilia (16%)
was noted. Serum creatinine peaked at 465 on day 46, when
the creatinine clearance was only 11 ml/min. By day 59 she
was normotensive and the U and E had returned to normal,
but 2 months later CrCl was only 51 ml/min and was still
reduced at 58 mls/min 2 years later.6. Case 5
Case 5 was a late diagnosis at age 51 years having
been treated for asthma and bronchiectasis in a generalDiabetes Pseudomonas antibiogram IV courses per year
1 year Multiresistant 5
No Multiresistant(Also B cenocepacia) 6
2 years Multiresistant 3
No Multiresistant 8
2 years Multiresistant 2
1 year Multiresistant 4
2 years Multiresistant 4
No Multiresistant 4
tics. This definition excludes colomycin.
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commenced on nebulised tobramycin (TOBI \) and
azithromycin.
In February 2004, she was hospitalised for a respiratory
exacerbation. TOBI \ was replaced with IV tobramycin
(120 mg tds :9 mg/kg/day) and IV colomycin 2 megaunits
tds. Pretreatment renal function was normal. Although
trough and peak tobramycin levels on days 2 and 4 were
satisfactory (1.1 and 9.1; 1.3 and 8.4 mg/l respectively), by
day 9 they were elevated (12.3 and 29.1) and renal function
was abnormal (Cr 285 Amol/l). Renal tract investigations
were normal, except for urine and peripheral blood
eosinophilia. Antibiotics and azithromycin were stopped
and she was treated conservatively with IV hydration. Three
days later random serum tobramycin was 1.1 mg/l.
Recovery of renal function was slow and 24 days later
CrCl was 41 ml/min. Due to her severe respiratory
morbidity nebulised TOBI and azithromycin were restarted
4 weeks later without immediate adverse effects on renal
function.7. Case 6
Case 6 was admitted in May 2001 for an exacerbation
and treated for 2 weeks with meropenem, colomycin (2
megaunits tds) and tobramycin (120 mg tds :6.5 mg/kg/
day; her usual dose is 140 mg tds). Tobramycin levels
were 2.3 and 9.0 pre- and post-4th dose respectively.
Levels were not adjusted, and U and E remained normal.
In June 2001 she had a further exacerbation, treated at
home with tobramycin (120 mg tds), colomycin (2
megaunits tds) and ceftazidime (3 g tds). On day 4 she
became pyrexial and developed a widespread macular rash.
Trough and peak tobramycin levels were 6.0 and 18
respectively. Urea was 10.5 mmol/l and creatinine 318
Amol/l. There was no evidence of a urinary tract infection
and renal USS was unremarkable. A blood eosinophilia of
11% and haematuria and eosinophilia in the urine sediment
suggested a drug induced allergic reaction. Antibiotics
were stopped and she insisted on discharge. U and E
returned to normal after 2 weeks, although on day 19 CrCl
was only 60 mls/min.8. Case 7
Case 7 was taking azithromycin as an anti-inflamma-
tory agent. In June 2000 she was treated at home with
gentamicin (120 mg tds :6.6mg/kg/day) and meropenem (1
g tds). Gentamicin levels were within the therapeutic range
(trough 1.0 and peak 8.3 mg/l) and U and E were normal.
She did not improve and on day 10 was hospitalised. At
day 15 gentamicin levels were 6.0 and 9.4 mg/l pre- and
post-dose respectively, on unchanged medication. Creati-
nine rose to 144. Gentamicin was stopped and subse-quently restarted (she would not accept an alternative in
view of previous allergic reactions or intolerance to many
antibiotics) at 120 mg bid with satisfactory levels there-
after. She was discharged with clinical improvement and
normal U and E at day 31. She represented 2 weeks later
with a further exacerbation. On this occasion she was
treated with tobramycin (140 g tds :7.6 mg/kg/day) and
meropenem (1 mg tds): pre- and post-4th dose tobramycin
levels were 7.9 and 16.8 mg/l respectively and tobramycin
was omitted for several doses and then recommenced at
80 mg bid on day 7. Subsequently tobramycin levels
remained in the therapeutic range (pre-dose <1 and post-
dose 8.7 – 10.1) for multiple assays taken between day 8
and 22. The first abnormal creatinine was noted on day 8
(157 Amol/l) and reverted to normal by day 14. Inves-
tigation of the renal tract failed to provide an alternative
explanation. Further more, on day 22 she complained of
dizziness, tinnitus, and deafness, and ENT review revealed
disequilibrium and high tone sensorineural deafness in
keeping with aminoglycoside toxicity. Tobramycin treat-
ment was withdrawn.9. Case 8
Case 8 underwent ureteric reimplantation for PUJ
obstruction/strictures and had recurrent urinary tract
infections as a young child, but had no episodes of
renal dysfunction as an adult. In October 2000 she
received 2 weeks of IV tobramycin (160 mg TDS) and
colomycin (2 megaunits tds) at home for a pulmonary
exacerbation with good effect and no adverse reactions.
The same treatment was repeated 5 weeks later for a
second exacerbation. Peak tobramycin levels >10 mg/l
on days 2 and 5 resulted in the dose being reduced in a
stepwise fashion to 100 mg tds. A trough tobramycin
assay of 2.9 on day 10 led to further reduction in dose
to 100 mg bid. U and E remained normal throughout.
By day 14 her respiratory symptoms and FEV1 had
improved but she complained of lethargy, nausea,
vomiting, fever, rigors and cloudy urine. She was
immediately admitted to hospital and the first abnormal
U and E recorded (urea 12.2; creatinine 190). Despite
abundant pus cells in the urinary sediment, MSSU and
blood cultures were sterile. A small calculus was
projected over the lower pole of the left kidney on a
plain abdominal X-ray. USS showed both kidneys to be
of normal size without significant scarring or obstruction
but the appearances of the parenchyma were in keeping
with bilateral pyelonephritis. Immunology screen was
negative. She was rehydrated with IV fluids and
tobramycin was replaced with meropenem. Her symp-
toms settled and U and E returned to normal over the
next 7 days, although CrCl was reduced to 12 ml/min.
Renal impairment was still evident 27 months later (CrCl
48 ml/min).
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The potential for aminoglycosides to cause renal damage
was first described in 1945 [4]. In common with other
renally excreted drugs, their serum concentrations are
reduced in patients with CF [5], who subsequently require
high doses to achieve therapeutic levels often over
prolonged courses. CF patients are therefore at particular
risk of aminoglycoside toxicity. Surprisingly however, there
are few reports of renal disease, and acute renal failure has
only recently been described in children in association with
gentamicin [2,6]. For the first time, we have shown
aminoglycoside toxicity in adult CF patients, mainly in
association with tobramycin which is, traditionally, thought
to be one of the less nephrotoxic aminoglycosides [7,8].
Aminoglycosides have a narrow therapeutic range, and
require careful monitoring of serum levels to prevent acute
toxic effects. Such toxicity results from a proportion of the
administered dose accumulating in the epithelial cells of the
proximal renal tubules, causing a stepwise alteration of cell
function ultimately leading to acute tubular necrosis [9].
Advancing toxicity is characterised by increased electrolyte
leak and finally renal failure is manifest by uraemia and high
serum creatinine concentration. In clinical practice, oliguric
or anuric renal failure is rare. Tubular damage may continue
for several days after cessation of aminoglycoside therapy
due to high parenchymal levels [9]. Indeed serum creatinine
continued to rise for a few days after aminoglycoside
withdrawal in cases 1, 3 and 4 in our series, and in some
recovery was protracted. None of our patients had oliguria/
anuria, abnormal serum electrolyte concentration or evi-
dence of glumerulonephritis and renal biopsy was not
performed since all cases recovered without the need for
dialysis. However, all were left with reduced creatinine
clearance (mean 52 mls/min [range 37–63]; mean interval
from episode of ARF 9 months [range 1–27]). In every case
serum urea and creatinine recovered from the acute event,
highlighting the insensitivity of these routine serum markers
for monitoring long term change in renal function.
Aminoglycosides are powerful antipseudomonal agents,
and have an important role in the treatment of patients with
CF, especially where multiresistant strains are present. In
our series, all patients were chronically infected by such a
multidrug resistant transmissible strain (the Liverpool
epidemic strain) that is generally only sensitive to tobra-
mycin and colomycin [10]. However, the reasons why these
patients developed renal toxicity related to aminoglycoside
use after many previous courses are unclear. Risk factors for
aminoglycoside toxicity include cumulative exposure, high
dosage, prolonged therapy, dehydration, concurrent neph-
rotoxic medication and pre-existing renal disease. All our
patients had previously received many courses of IV
aminoglycosides without overt ill effect (mean 6.8 courses
in the preceding 2 years [range 4–11]), and their dosage
had been correctly monitored (average 10 satisfactory
paired serum tobramycin levels per patient [range 6–18]).Their pulmonary function and nutritional state did not
change significantly over this period. Also, the dosages of
aminoglycoside were within the UK CF Trust guidelines
[11] (mean 8.8 mg/kg/day, [range 6.5–10.3]), and with the
exception of case 4 (duration 39 days), none were subjected
to unusually prolonged treatment (mean 9.8 days [range 4–
16] at diagnosis of acute renal toxicity). The close
proximity of 2 courses in cases 6, 7 and 8 may have
played a part in precipitating renal injury. Only one patient
had evidence of pre-existing renal anomaly and none had
features of obstructive uropathy or connective tissue
disorder/vasculitis.
There are several possible contributory factors potentiat-
ing the development of acute renal failure in our series of
patients. All patients were on combination antibiotic therapy
in keeping with current best practice for CF [11], and B
lactam antibiotics have been implicated in drug induced
acute tubulo-interstitial nephritis (TIN)[12]. In theory, acute
TIN may complicate CF as a result of an allergic reaction to
many drugs [13], but there is only one report of this
complication in CF patients [2]. In our series, renal
specialist review concluded that the substitution of ceftazi-
dime for meropenem (case 6) and the introduction of
azithromycin (cases 4 and 5) may be relevant: these cases
developed peripheral blood eosinophilia and renal sedi-
ments in keeping with drug induced TIN [12]. Azithromy-
cin, a macrolide antibiotic increasingly used for its immune
modulatory effect in CF, has also been shown to precipitate
TIN [14], but this has not been described in CF patients.
Also, there are no reports of an interaction between
azithromycin and aminoglycosides, and the pharmacoki-
netics of azithromycin are not significantly altered in
patients with mild to moderate renal insufficiency [15].
None of our patients taking azithromycin were on statins,
cyclosporin or other immunosuppressive therapy, as inter-
actions with these agents have been reported to induce ARF
[16,17]. Obviously, as TIN induced renal impairment results
in increased aminoglycoside levels, it will further exacerbate
aminoglycoside related nephrotoxicity. TIN is unpredictable
and can happen at any time after introduction of the drug
[12].
Also, many of our patients were also receiving con-
current non-steroidal anti-inflammatory drugs (NSAIDs),
which have previously been reported to interact with
aminoglycosides in CF patients [3,18]. These are frequently
administered in adult CF patients, who may present with
posture-related musculoskeletal chest or back pain as well as
CF-related arthropathy. NSAIDs inhibit intrarenal produc-
tion of the vasodilator prostaglandin E2 and prostacyclin,
causing renal vasoconstriction and acute renal dysfunction
[19]. This is relevant only in extracellular volume contracted
states, when renal blood flow is dependent on prostaglandin
production. It is therefore essential to monitor renal function
in CF patients taking NSAIDS particularly if they are
unwell, dehydrated and receiving IVaminoglycosides (cases
1, 2 and 3).
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be a simple process and can be influenced by several
interrelated factors. Our cases illustrate one of the difficul-
ties encountered in treating adult CF patients infected with
multiresistant epidemic P. aeruginosa, in particular LES.
This strain is prevalent amongst CF patients in Liverpool,
and is widespread throughout CF clinics in the UK [20].
Prevention of the spread of such organisms within the CF
community is essential, and this can only be achieved
through the implementation of strict segregation policies.
Avoidance of aminoglycosides is rarely an option as the
emergence of these resistant strains compels their use.
Instead, we suggest that emphasis should be on reducing
their harm by choosing less toxic aminoglycosides, alter-
nating classes of antipseudomonal antibiotics to increase the
interval between course exposures to allow complete drug
clearance, and increased vigilance when aminoglycosides
are used concurrently with other potentially nephrotoxic
drugs. Careful monitoring of drug levels is paramount
particularly if there is a potentially dehydrating state or pre-
existing renal anomaly. We have recently shown that adult
CF patients have occult renal damage associated with long-
term exposure to aminoglycosides [1]. In those paediatric
CF units where routine 3 monthly IV antibiotic courses are
offered (which has not been shown to be beneficial) [21]
aminoglycosides should be avoided where possible. As
survival in CF continues to improve, the incidence of drug
induced renal injury may increase, strengthening the case
for screening/surveillance for aminoglycoside induced
toxicity. Measurement of creatinine clearance and an
assessment of the interval aminoglycoside exposure at each
annual screen may be a useful aid.References
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